Key result
Nebivolol increases nitric oxide by ~68% vs metoprolol in hypertensive kidney transplant recipients under 50.
Why the study?
The effects of nebivolol versus metoprolol on nitric oxide blood level, eGFR, and blood pressure in hypertensive kidney transplant recipients had not been previously reported.
Does nebivolol improve blood nitric oxide levels, blood pressure, and renal function in hypertensive kidney transplant recipients compared to metoprolol?
RCT (n=30)
Open-label
randomized
Does nebivolol improve blood nitric oxide levels, blood pressure, and renal function in hypertensive kidney transplant recipients compared to metoprolol?
Nebivolol increases blood nitric oxide levels in hypertensive kidney transplant recipients younger than 50 years compared to metoprolol, without significant differences in blood pressure or renal function.
Answers are grounded in this paper and cite their sources.
Favors nebivolol for nitric oxide elevation in younger kidney transplant recipients; extends beta-blocker comparative data without BP or renal differences.
In hypertensive kidney transplant recipients, the effects of nebivolol vs metoprolol on nitric oxide (NO) blood level, estimated glomerular filtration rate (eGFR), and blood pressure (BP) have not been previously reported. In a 12-month prospective, randomized, open-label, active-comparator trial, hypertensive kidney transplant recipients were treated with nebivolol (n=15) or metoprolol (n=15). Twenty-nine patients (nebivolol [n=14], metoprolol [n=15]) completed the trial. The primary endpoint was change in blood NO level after 12 months of treatment. Secondary endpoints were changes in eGFR, BP, and number of antihypertensive drug classes used. After 12 months of treatment, least squares mean change in plasma NO level in the nebivolol kidney transplant recipient group younger than 50 years was higher by 68.19% (99.17% confidence interval [CI], 13.02-123.36), 69.54% (99.17% CI, 12.71-126.37), and 66.80% (99.17% CI, 12.95-120.64) compared with the metoprolol group younger than 50 years, the metoprolol group 50 years and older, and the nebivolol group 50 years and older, respectively. The baseline to month 12 change in mean arterial BP, eGFR, and number of antihypertensive drug classes used was not significantly different between the treatment groups. In hypertensive kidney transplant recipients, nebivolol use in patients younger than 50 years increased blood NO.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2015) conducted an RCT in Hypertensive kidney transplant recipients (n=30). Nebivolol vs. Metoprolol was evaluated on change in blood NO level after 12 months of treatment (MD 68.19%, 95% CI 13.02-123.36). In hypertensive kidney transplant recipients younger than 50 years, nebivolol increased plasma nitric oxide levels by 68.19% compared with metoprolol over 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: